Palopegteriparatide

CHEMBL5095475 Phase 4 ได้รับการอนุมัติ Protein
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

A PEGylated form of parathyroid hormone (PTH 1-34) that provides a more sustained release and longer duration of action than standard teriparatide, used to treat hypoparathyroidism. By replacing the missing parathyroid hormone, it helps regulate calcium and phosphate levels in the blood.

กลไกการออกฤทธิ์

Mimics or modulates parathyroid hormone activity to stimulate osteoblast-mediated bone formation, increasing bone mineral density and reducing fracture risk.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Mimics or modulates parathyroid hormone activity to stimulate osteoblast-mediated bone formation, increasing bone mineral density and reducing fracture risk.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

A PEGylated form of parathyroid hormone (PTH 1-34) that provides a more sustained release and longer duration of action than standard teriparatide, used to treat hypoparathyroidism. By replacing the missing parathyroid hormone, it helps regulate calcium and phosphate levels in the blood.

Mimics or modulates parathyroid hormone activity to stimulate osteoblast-mediated bone formation, increasing bone mineral density and reducing fracture risk.

Yes, Palopegteriparatide is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL5095475. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.